Drug Discovery Opinion

Transcription factors – proteins that bind to specific DNA sequences and promote or block transcription – are essential for correct regulation of gene expression. Since many transcription factors are tumour suppressors or oncogenes, and mutations are associated with the development of different types of cancer, they have been the subject of intense interest. As a class, however, they have proved to be difficult drug targets since the vast majority of transcription factors lack an appropriate binding pocket for targeting by small molecules and, since most are intracellular, they are not suitable for antibody-based therapies. A team of US scientists have now discovered a way to modulate activity of the transcription factor, Notch, which is often mutated or damaged in patients with T-cell acute lymphoblastic leukaemia (T-ALL). Abnormalities in Notch signalling also underlie a variety of other cancers, including lung, ovarian, pancreatic and gastrointestinal cancers. The structure of Notch binding to other proteins in the transactivation complex revealed a long shallow helical groove at one of the protein-protein interfaces, and the team designed compounds that bind in this region and prevent complex assembly. The compounds are ‘stapled peptides’, held in a complementary helical shape by hydrocarbon crosslinks. Experiments in cultured T-ALL cells, and in a mouse leukaemia model, showed that one of the compounds, SAHM1, was able to limit the growth of cancer cells controlled exclusively by Notch, but did not inhibit the growth of cells that were not regulated by Notch. At a molecular level, the peptide reduced expression of genes that are controlled directly and indirectly by Notch.

The direct inhibition of Notch did not produce the gastrointestinal toxicity which has been observed with inhibition of Notch processing by γ-secretase inhibitors, but further experiments will be needed to ensure that side effects are not caused by blocking this highly conserved and important signalling pathway.

As well as identifying a compound that inhibits Notch signalling, the work could also lead to inhibitors of other transcription factors that assemble in a similar way to Notch and are associated with conditions such as diabetes and autoimmune diseases. Despite being considerably larger than typical small molecule drugs, the ‘stapled peptides’ are able to penetrate cells since they are taken up by an active transport mechanism.

The study is published in the journal Nature.

Aileron Therapeutics are spearheading the development of stapled peptides to modulate protein-protein interactions.

Related posts:

1. SkelGen – A Newly Available Tool for Computational Drug Design With the rapidly growing body of biostructural information, structure-based drug design has increased in importance and a variety of computational...
2. Yeast Cells: Drug Discovery Factories Whitehead Institute researchers have described a new drug discovery technique which uses yeast cells to both synthesise and screen novel...
3. Extracurricular Role for ERK2 as a Transcription Factor Scientists at Johns Hopkins School of Medicine set out to systematically map protein-DNA interactions across the human genome using a...
4. Progress in Drug Discovery for Spinal Muscular Atrophy Spinal Muscular Atrophy (SMA) describes a group of diseases where motor neurons of the spinal cord and brain stem, which...
5. Drug Discovery Data for All On Monday the European Molecular Biology Laboratory’s European Bioinformatics Institute (EMBL-EBI) announced ChEMBLdb, a drug discovery database containing information on...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Friday, November 13th, 2009 at 8:43 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.